Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Congratulations are in order for Associate Professor Samira Lakhal-Littleton, who has been awarded a Senior Non-Clinical Fellowship by the Medical Research Council to further her lab's work exploring the implications of the cardiac hepcidin/ferroportin axis for the management of iron deficiency in heart failure.

Over the past six years, research in the Lakhal-Littleton lab has uncovered the mechanisms and importance of local iron control in the heart, lung, kidney and fetal liver. In 2016, the lab published the first study describing the mechanism linking iron deficiency with heart disease. In 2019, the lab revealed a critical link between iron deficiency and pulmonary arterial hypertension (PAH), finding that iron deficiency within the smooth muscle cells of the pulmonary arteries is in itself sufficient to cause PAH, even in the absence of anaemia. This year, the lab challenged assumptions on fetal iron development during pregnancy by revealing that fetal liver hepcidin plays a key role in determining iron endowment in the newborn baby, demonstrating that medical advice given to pregnant women, particularly around iron supplements, should take fetal iron levels into account, not just the mother's haemoglobin levels.

These discoveries and more have changed our understanding of the pathophysiology of iron deficiency of chronic disease, and have important implications for the management of iron deficiency in patients with chronic conditions such as chronic heart failure, chronic kidney disease and chronic obstructive pulmonary disease.

Associate Professor Samira Lakhal-Littleton has now been awarded an MRC Senior Non-Clinical Fellowship to further the cardiovascular aspect of her lab's work. The award will enable her team to work to understand how the iron homeostatic hormone hepcidin, which tends to be elevated in early stages of heart failure, modifies both the course of disease and the outcome of the iron treatment used to correct iron deficiency in heart failure patients.

 

This fellowship provides significant support over 5 years, to help translate the basic understanding gained thus far into better management of iron deficiency in patients with heart failure. - Prof Lakhal-Littleton

The Senior Non-Clinical Fellowships are designed to facilitate independent researchers with a track record of effectively leading their own research to become internationally recognised leaders in their field. More information on the Fellowship can be found on the Medical Research Council website.

Similar stories

Travels with Vignesh

CRM General

Vignesh Murugesan, a Postdoctoral Researcher in Department of Physiology, Anatomy & Genetics (DPAG), describes how he found his way from the large metropolitan town of Chennai in India to studying regenerative medicine here in Oxford, via an 8 year stint in Sweden.

Genetic breakthrough to target care for deadly heart condition

CRE Research

Professor Watkins and his team have found a new type of genetic change in the DNA of people with hypertrophic cardiomyopathy (HCM) - a silent killer amongst families that can cause sudden death in young people due to the thickening of the heart muscle.

Earliest origins of the forming heart identified

CRE Research

The earliest known progenitor of the outermost layer of the heart has been characterised for the first time and linked to the development of other critical cell types in the developing heart in a new paper from the Srinivas group led by BHF Immediate Fellow Dr Richard Tyser.

Professor Sir Rory Collins awarded the MRC Millennium Medal 2020

CRE Research

Professor Sir Rory Collins, Head of the Nuffield Department of Population Health, and Principal Investigator and Chief Executive of UK Biobank, has been awarded the Medical Research Council (MRC) Millennium Medal 2020, the MRC’s most prestigious personal award.

New MRI technique could detect early signs of heart failure in cancer patients following chemotherapy

CRE Publication Research

New research led by Oxford BHF CRE Intermediate Transition Fellow Dr Kerstin Timm shows that a recently developed imaging technique pioneered by the Tyler Group can detect early metabolic changes in the heart caused by a commonly used chemotherapy drug, which is known to increase risk of heart failure in cancer survivors.